Hsp90 inhibitors: a potential treatment for latent EBV infection?
Sun
Xiaoping
X
Department of Oncology, McArdle Laboratory for Cancer Research, University of Wisconsin, School of Medicine and Public Health, Madison, WI, USA.
Kenney
Shannon C
SC
D000998:Antiviral Agents / Q000627:therapeutic use; D016227:Benzoquinones / Q000627:therapeutic use; D004151:Dipeptides / Q000627:therapeutic use; D020031:Epstein-Barr Virus Infections / Q000188:drug therapy*; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D004854:Herpesvirus 4, Human; D006801:Humans; D047029:Lactams, Macrocyclic / Q000627:therapeutic use; D014764:Viral Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism
D000998:Antiviral Agents; D016227:Benzoquinones; D004151:Dipeptides; D018841:HSP90 Heat-Shock Proteins; D047029:Lactams, Macrocyclic; D014764:Viral Proteins; C112765:tanespimycin; C065992:N-glycylalanine; C001277:geldanamycin
Cell. 1997 Jul 11;90(1):65-75
9230303
Curr Top Med Chem. 2009;9(15):1436-46
19860732
Nature. 2003 Sep 25;425(6956):407-10
14508491
Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9319-24
18591662
Science. 2003 Sep 5;301(5638):1371-4
12958359
Curr Opin Pharmacol. 2008 Aug;8(4):370-4
18644253
Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12616-21
9356498
Genes Dev. 2007 Jan 15;21(2):195-205
17234885
Mol Biol Cell. 2006 Feb;17(2):824-33
16314389
Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3146-51
20133771
Plasmid. 2007 Jul;58(1):1-12
17350094